Abstract

BackgroundGlioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Despite a multimodal therapy consisting of resection followed by fractionated radiotherapy (RT) combined with the chemotherapeutic agent (CT) temozolomide (TMZ), its recurrence is almost inevitable. Since the immune system is capable of eliminating small tumor masses, a therapy should also aim to stimulate anti-tumor immune responses by induction of immunogenic cell death forms. The histone deacetylase inhibitor valproic acid (VPA) might foster this.MethodsReflecting therapy standards, we applied in our in vitro model fractionated RT with a single dose of 2Gy and clinically relevant concentrations of CT. Not only the impact of RT and/or CT with TMZ and/or VPA on the clonogenic potential and cell cycle of the glioblastoma cell lines T98G, U251MG, and U87MG was analyzed, but also the resulting cell death forms and release of danger signals such as heat-shock protein70 (Hsp70) and high-mobility group protein B1 (HMGB1).ResultsThe clonogenic assays revealed that T98G and U251MG, having mutated tumor suppressor protein p53, are more resistant to RT and CT than U87MG with wild type (WT) p53. In all glioblastoma cells lines, fractionated RT induced a G2 cell cycle arrest, but only in the case of U87MG, TMZ and/or VPA alone resulted in this cell cycle block. Further, fractionated RT significantly increased the number of apoptotic and necrotic tumor cells in all three cell lines. However, only in U87MG, the treatment with TMZ and/or VPA alone, or in combination with fractionated RT, induced significantly more cell death compared to untreated or irradiated controls. While necrotic glioblastoma cells were present after VPA, TMZ especially led to significantly increased amounts of U87MG cells in the radiosensitive G2 cell cycle phase. While CT did not impact on the release of Hsp70, fractionated RT resulted in significantly increased extracellular concentrations of Hsp70 in p53 mutated and WT glioblastoma cells.ConclusionsOur results indicate that fractionated RT is the main stimulus for induction of glioblastoma cell death forms with immunogenic potential. The generated tumor cell microenvironment might be beneficial to include immune therapies for GBM in the future.

Highlights

  • Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults

  • Williams et al analyzed the clonogenic potential of 39 tumor cell lines and found the three human glioblastoma cell lines T98G, U251MG, and U87MG as the most resistant cell lines in a dose range 2-10Gy [46,47]

  • Our data show that T98G and U251MG, which express methylguanine methyltransferase (MGMT) and contain mutant p53, are more resistant to radiation than U87MG with no MGMT expression and p53 wild type (WT) (Figure 1)

Read more

Summary

Introduction

Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Despite a multimodal therapy consisting of resection followed by fractionated radiotherapy (RT) combined with the chemotherapeutic agent (CT) temozolomide (TMZ), its recurrence is almost inevitable. Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor in adults. It is characterized by its aggressive, diffuse infiltrative and invasive growth. Because of the infiltrative growth of the tumor a complete resection is difficult and radiation (RT) mostly combined with chemotherapy (CT) follow as adjuvant treatments. The most widely used chemotherapeutics in GBM treatment are alkylating agents, including the well tolerated imidazoletetrazinone derivative temozolomide (TMZ), since the lipophilic properties allow to pass the blood brain barrier. Stupp et al reported about an improved median survival from 12.1 to 14.6 months and an increased 5-years survival from 1.9% to 9.8% of patients with GBM treated with concomitant and adjuvant TMZ and RT compared to RT alone [2]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call